EWS/FLI utilizes NKX2-2 to repress mesenchymal features of Ewing sarcoma.
about
Therapeutic opportunities in Ewing sarcoma: EWS-FLI inhibition via LSD1 targetingPotential approaches to the treatment of Ewing's sarcomaThe histone demethylase KDM3A, and its downstream target MCAM, promote Ewing Sarcoma cell migration and metastasis.Inhibition of porcupine prolongs metastasis free survival in a mouse xenograft model of Ewing sarcoma.Usefulness of NKX2.2 Immunohistochemistry for Distinguishing Ewing Sarcoma from Other Sinonasal Small Round Blue Cell Tumors.
P2860
EWS/FLI utilizes NKX2-2 to repress mesenchymal features of Ewing sarcoma.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
EWS/FLI utilizes NKX2-2 to repress mesenchymal features of Ewing sarcoma.
@en
type
label
EWS/FLI utilizes NKX2-2 to repress mesenchymal features of Ewing sarcoma.
@en
prefLabel
EWS/FLI utilizes NKX2-2 to repress mesenchymal features of Ewing sarcoma.
@en
P2093
P2860
P1433
P1476
EWS/FLI utilizes NKX2-2 to repress mesenchymal features of Ewing sarcoma.
@en
P2093
Laura M Hoffman
Mary C Beckerle
Michael E Engel
Russell Bell
Stephen L Lessnick
P2860
P304
P356
10.18632/GENESANDCANCER.57
P50
P577
2015-03-01T00:00:00Z